Barclays’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Barclays’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-37,971	Closed	-$1.76M	–	4792
2023 Q2	$1.76M	Buy	37,971 +16,655	+78%	+$576K	﹤0.01%	1963
2023 Q1	$611K	Buy	21,316 +8,179	+62%	+$242K	﹤0.01%	3126
2022 Q4	$410K	Buy	13,137 +7,181	+121%	+$234K	﹤0.01%	3435
2022 Q3	$120K	Buy	5,956 +4,531	+318%	+$82.6K	﹤0.01%	3466
2022 Q2	$22K	Sell	1,425 -1,436	-50%	-$24.7K	﹤0.01%	4365
2022 Q1	$55K	Buy	+2,861	New	+$51.1K	﹤0.01%	4083

Barclays's DICE Position: Q3 2023 in Review

Barclays sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 37,971 shares — an estimated $1.76M sold.

Barclays first reported a position in DICE in Q1 2022 and held it in 6 quarters. The position peaked at $1.76M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Barclays reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Barclays sold 37,971 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.76M.
Barclays first reported a position in DICE Therapeutics, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
Barclays's DICE Therapeutics, Inc. Common Stock position peaked at $1.76M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.